Artwork

محتوای ارائه شده توسط Health Professional Radio. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Health Professional Radio یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !

Scholar Rock - Positive Top-Line Results from TOPAZ Trial - Type 2 and 3 SMA

10:23
 
اشتراک گذاری
 

بایگانی مجموعه ها ("فیدهای غیر فعال" status)

When? This feed was archived on October 25, 2022 13:32 (1+ y ago). Last successful fetch was on May 03, 2022 16:48 (2y ago)

Why? فیدهای غیر فعال status. سرورهای ما، برای یک دوره پایدار، قادر به بازیابی یک فید پادکست معتبر نبوده اند.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 292216799 series 1076397
محتوای ارائه شده توسط Health Professional Radio. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Health Professional Radio یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Dr. Yung Chyung, Chief Medical Officer at Scholar Rock, a clinical-stage biopharmaceutical company discusses the positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).

Dr. Yung H. Chyung has served as Chief Medical Officer since February 2016 and leads the clinical development of pipeline candidates and medical affairs. Prior to joining Scholar Rock, Yung served in roles of increasing responsibility at Dyax Corp. (acquired by Shire Plc in January 2016) from 2011 to February 2016, most recently serving as Vice President of Medical Research, where he was responsible for clinical research and medical affairs. From 2010 to 2011, he worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple rare disease programs. Yung earned his MD from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an AB in Biochemical Sciences from Harvard College.

  continue reading

683 قسمت

Artwork
iconاشتراک گذاری
 

بایگانی مجموعه ها ("فیدهای غیر فعال" status)

When? This feed was archived on October 25, 2022 13:32 (1+ y ago). Last successful fetch was on May 03, 2022 16:48 (2y ago)

Why? فیدهای غیر فعال status. سرورهای ما، برای یک دوره پایدار، قادر به بازیابی یک فید پادکست معتبر نبوده اند.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 292216799 series 1076397
محتوای ارائه شده توسط Health Professional Radio. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Health Professional Radio یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Dr. Yung Chyung, Chief Medical Officer at Scholar Rock, a clinical-stage biopharmaceutical company discusses the positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).

Dr. Yung H. Chyung has served as Chief Medical Officer since February 2016 and leads the clinical development of pipeline candidates and medical affairs. Prior to joining Scholar Rock, Yung served in roles of increasing responsibility at Dyax Corp. (acquired by Shire Plc in January 2016) from 2011 to February 2016, most recently serving as Vice President of Medical Research, where he was responsible for clinical research and medical affairs. From 2010 to 2011, he worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple rare disease programs. Yung earned his MD from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an AB in Biochemical Sciences from Harvard College.

  continue reading

683 قسمت

همه قسمت ها

×
 
Loading …

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

 

راهنمای مرجع سریع